GE Healthcare Technologies Inc (GEHC)
NASDAQ:GEHC
Want to see GEHC full AI Analyst Report?
Top Page
GE Healthcare Technologies Inc
(NASDAQ:GEHC)
Select Model
Select Model
Rating:56Neutral
Price Target:
$71.00
▼(-4.90% Downside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weakening recent TTM profitability/cash flow and a bearish technical setup (below key moving averages with negative MACD). Elevated valuation (high P/E and low yield) also limits upside. Offsetting factors include maintained organic growth guidance, strong backlog/book-to-bill, and management actions to mitigate inflation/tariff pressures.
Positive Factors
Record backlog & book-to-bill
A record $21.8B backlog and a book-to-bill >1 give multi-quarter revenue visibility, smoothing capital equipment cyclicality. This backlog supports near-term revenue delivery, underpins service attach rates and helps sustain recurring revenue and cash flow over the next 2–6 months.
Negative Factors
Material inflation & tariffs
Approximately $250M of gross inflation and recurring tariff pressures compress margins and force price or cost actions. These structural input-cost risks can persist intermittently across supply chains and geographies, reducing margin sustainability and delaying earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Record backlog & book-to-bill
A record $21.8B backlog and a book-to-bill >1 give multi-quarter revenue visibility, smoothing capital equipment cyclicality. This backlog supports near-term revenue delivery, underpins service attach rates and helps sustain recurring revenue and cash flow over the next 2–6 months.
Read all positive factors
GE Healthcare Technologies Inc (GEHC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.16B
Dividend Yield0.17%
Average Volume (3M)3.48M
Price to Earnings (P/E)50.9
Beta (1Y)1.27
Revenue Growth4.85%
EPS Growth4.69%
CountryUS
Employees53,000
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.99
Shares Outstanding456,290,130
10 Day Avg. Volume3,020,461
30 Day Avg. Volume3,483,940
Financial Highlights & Ratios
PEG Ratio4.13
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda11.64
Forecast
1Y Price Target
$86.92Price Target Upside16.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)5.06
Revenue Forecast (FY)$21.71B
GE Healthcare Technologies Inc Business Overview & Revenue Model
Company Description
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, th...
How the Company Makes Money
GEHC primarily makes money by selling and supporting healthcare technology used in clinical settings. Key revenue streams include: (1) Equipment and system sales: one-time sales of capital equipment such as imaging systems (e.g., CT, MRI, X-ray), ...
GE Healthcare Technologies Inc Key Performance Indicators (KPIs)
Any
Remaining Performance Obligations by Type
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Data provided by:
The Fly
The FlyGE Healthcare Technologies Inc Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call balanced encouraging top-line execution, product/regulatory milestones, a record backlog and strategic progress (Flyrcado ramp, Photonova approvals, Intelerad acquisition, organizational realignment) against meaningful near-term profitability headwinds from supplier issues, tariffs and material inflation (~$250M gross impact). Management maintained revenue guidance but prudently reduced earnings guidance and emphasized mitigation actions whose benefits are weighted to the back half of 2026. The tone was confident on medium-term growth while realistic on near-term margin pressure.Positive Updates
Top-Line Growth and Revenue Beat
Q1 revenue of $5.1B, +2.9% organic YoY, came in at the high end of guidance; product and service revenues showed strong reported growth of +7.3% and +7.5% respectively.
Negative Updates
Margin and EPS Pressure in Q1
Adjusted EBIT margin declined ~150 bps YoY to 13.5%; adjusted EPS of $0.99 was below expectations and included roughly $0.16 of tariff impact.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth and Revenue Beat
Q1 revenue of $5.1B, +2.9% organic YoY, came in at the high end of guidance; product and service revenues showed strong reported growth of +7.3% and +7.5% respectively.
Read all positive updates
Company Guidance
GE HealthCare maintained revenue guidance of 3%–4% organic sales growth (Q2 also guided 3%–4%), expects an approximate 100-basis-point FX tailwind to revenue, and set full-year adjusted EBIT margin at 15.4%–15.7% (up ~10–40 bps year‑over‑year) with adjusted EPS now $4.80–$5.00 (≈5%–9% growth YoY, and a low‑single‑digit EPS decline expected in Q2); management called out a gross inflation headwind of roughly $250 million (~$0.43/share) — driven by about $100M memory chips, $100M oil/freight and ~$50M metals/other — of which they expect to offset more than half via price and cost actions (they reduced EPS by $0.15 for the remaining inflation effect), expect tariffs to be lower than 2025 (Q1 contained the largest tariff hit and adjusted EPS included ~ $0.16 of tariff impact), and now forecast free cash flow of approximately $1.6 billion (supported by a 1.07x book‑to‑bill and a record $21.8 billion backlog).GE Healthcare Technologies Inc Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
64
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.95B | 20.63B | 19.67B | 19.55B | 18.34B | 17.59B |
| Gross Profit | 8.49B | 8.25B | 8.21B | 7.92B | 7.18B | 7.17B |
| EBITDA | 3.16B | 3.79B | 3.67B | 3.51B | 3.17B | 3.54B |
| Net Income | 1.50B | 2.08B | 1.99B | 1.57B | 1.92B | 2.25B |
Balance Sheet | ||||||
| Total Assets | 37.13B | 36.91B | 33.09B | 32.45B | 27.54B | 26.31B |
| Cash, Cash Equivalents and Short-Term Investments | 2.29B | 4.51B | 2.89B | 2.50B | 1.45B | 556.00M |
| Total Debt | 7.00M | 10.00B | 9.38B | 9.86B | 8.63B | 437.00M |
| Total Liabilities | 26.23B | 26.31B | 24.44B | 25.14B | 17.95B | 9.41B |
| Stockholders Equity | 10.67B | 10.38B | 8.45B | 7.13B | 9.36B | 16.66B |
Cash Flow | ||||||
| Free Cash Flow | 1.23B | 1.51B | 1.55B | 1.71B | 1.80B | 1.36B |
| Operating Cash Flow | 1.74B | 1.99B | 1.95B | 2.10B | 2.11B | 1.61B |
| Investing Cash Flow | -3.14B | -1.05B | -914.00M | -558.00M | -398.00M | -1.76B |
| Financing Cash Flow | 924.00M | 617.00M | -573.00M | -478.00M | -822.00M | -263.00M |
GE Healthcare Technologies Inc Technical Analysis
Neutral
74.66
Price Trends
75.66
Negative
79.02
Negative
76.76
Negative
Market Momentum
-0.20
Negative
54.63
Neutral
75.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Neutral. The current price of 74.66 is above the 20-day moving average (MA) of 71.85, below the 50-day MA of 75.66, and below the 200-day MA of 76.76, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 54.63 is Neutral, neither overbought nor oversold. The STOCH value of 75.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GEHC.
GE Healthcare Technologies Inc Risk Analysis
GE Healthcare Technologies Inc disclosed 32 risk factors in its most recent earnings report. GE Healthcare Technologies Inc reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GE Healthcare Technologies Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $7.06B | 34.29 | 10.11% | ― | 9.47% | 124.24% | |
75 Outperform | $26.21B | 36.72 | 13.41% | ― | 16.34% | 25.89% | |
71 Outperform | $4.55B | 33.71 | 22.89% | ― | 15.92% | 18.07% | |
64 Neutral | $3.55B | -6.96 | -132.16% | ― | 50.58% | -3458.24% | |
56 Neutral | $32.16B | 50.87 | 17.11% | 0.17% | 4.85% | 4.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $9.45B | -47.49 | -59.95% | ― | 83.41% | 70.36% |
* Healthcare Sector Average
GEHC
GE Healthcare Technologies Inc
68.50
0.53
0.78%
VEEV
Veeva Systems
158.49
-73.15
-31.58%
HQY
Healthequity
81.18
-5.24
-6.06%
DOCS
Doximity
24.57
-33.18
-57.45%
TEM
Tempus AI, Inc. Class A
51.10
-3.19
-5.88%
HNGE
Hinge Health, Inc. Class A
44.74
4.58
11.40%
GE Healthcare Technologies Inc Corporate Events
Executive/Board Changes
GE HealthCare Announces Board Changes and New Director Appointment
Neutral
Mar 17, 2026
On March 13, 2026, GE HealthCare Technologies Inc. appointed Kevin A. Lobo to its Board of Directors, with his term running until the 2026 Annual Meeting of Stockholders, and named him to the Talent, Culture, and Compensation Committee, with compe...
Business Operations and StrategyPrivate Placements and Financing
GE HealthCare Establishes New 364-Day Revolving Credit Facility
Neutral
Feb 27, 2026
On February 26, 2026, GE HealthCare Technologies Inc. entered into a new 364-day senior unsecured revolving credit agreement with JPMorgan Chase Bank and a syndicate of lenders, establishing a $0.5 billion committed facility that matures on Februa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.